Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results.

"CONFLICT OF INTEREST Johnny Mahlangu has served as a consultant or on advisory boards for Baxalta, BioMarin, CSL Behring, Catalyst Biosciences, Novo Nordisk, Roche and Spark; served on speakers’ bureaus for Novo Nordisk, Pfizer, Roche, Sanofi, Springer, and Takeda; and received research grants from Baxalta, BioMarin, Catalyst Biosciences, CSL, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Spark, Roche, and uniQure. Jose Luis Lamas and Daniel R. Malan report no conflicts to disclose. Juan Cristobal Morales has served on speakers’ bureaus for Novo Nordisk and Roche; served on advisory boards for BioMarin and Novo Nordisk, and received fellowship support from Novo Nordisk, Roche, and Takeda. John Teeter, Robert J. Charnigo, Eunhee Hwang, and Steven Arkin are employees of Pfizer Inc. and may own stock/options in the company."

"FUNDING INFORMATION This study was sponsored by Pfizer Inc."